ABSTRACT Transforming growth factor-β (TGF-β) plays an important role in smooth muscle (SM) differentiation, but the downstream target genes regulating the differentiation process remain largely unknown. In this study, we identified olfactomedin 2 (Olfm2) as a novel regulator mediating SM differentiation. Olfm2 was induced during TGF-β-induced SM differentiation of human embryonic stem cell-derived mesenchymal cells. Olfm2 knockdown suppressed TGF-β-induced expression of SM markers, including SM α-actin, SM22α, and SM myosin heavy chain, whereas Olfm2 overexpression promoted the SM marker expression. TGF-β induced Olfm2 nuclear accumulation, suggesting that Olfm2 may be involved in transcriptional activation of SM markers. Indeed, Olfm2 regulated SM marker expression and promoter activity in a serum response factor (SRF)/CArG box-dependent manner. Olfm2 physically interacted with SRF without affecting SRF-myocardin interaction. Olfm2-SRF interaction promoted the dissociation of SRF from HERP1, a transcriptional repressor. Olfm2 also inhibited HERP1 expression. Moreover, blockade of Olfm2 expression inhibited TGF-β-induced SRF binding to SM gene promoters in a chromatin setting, whereas overexpression of Olfm2 dose dependently enhanced SRF binding. These results demonstrate that Olfm2 mediates TGF-β-induced SM gene transcription by empowering SRF binding to CArG box in SM gene promoters.
INTRODUCTION
Vascular smooth muscle (SM) differentiation is an essential component of vascular development. The alterations in the differentiated state of the SM contribute to a variety of major cardiovascular diseases, including atherosclerosis, hypertension, restenosis, and vascular aneurysms (Schwartz, 1983 (Schwartz, , 1997 Kocher and Gabbiani, 1986; Glukhova et al., 1988; Aikawa et al., 1993; Libby, 2001; Owens et al., 2004) . A hallmark of this SM phenotypic plasticity is the altered transcription of SM-specific differentiation genes, including SM α-actin (α-SMA), SM22α, and SM myosin heavy chain (SMMHC; Regan et al., 2000) . Serum response factor (SRF), a widely expressed MCM1, Agamous, Deficiens, SRF-box transcription factor, binds as a homodimer to a DNA consensus sequence known as a CArG box (CC(A/T) 6 GG), which is found in the promoter regions of SM-specific genes. SRF-CArG association is required for transcriptional activation of SM genes (Miano, 2003) . A large number of environmental cues, including growth factors/inhibitors, inflammatory mediators, and cell-cell and cell-matrix interactions, have been shown to regulate SM differentiation. Transforming growth factor-β (TGF-β) is among the most potent soluble growth factors that activate SM contractile gene expression in specified SM and non-SM types (Hirschi et al., 1998; Hu et al., 2003; Masszi et al., 2003; Chen and Lechleider, 2004; Sinha et al., 2004; Deaton et al., 2005; Tang et al., 2010) .
SM originates from multiple sources during vascular development. Various in vitro model systems have been developed to mimic SM development in vivo, including C3H10T1/2 cells, neural crest cells, A404, embryoid body, and embryonic stem cells (Hirschi et al., plays an important role in TGF-β-induced SM differentiation. Olfm2 was up-regulated along with the expression of SM markers in TGF-β-treated hES-MCs. TGF-β also induced the nuclear accumulation of Olfm2. Both gain-and loss-of-function studies indicated that Olfm2 was essential for the expression of SM markers. Olfm2 promoted SM differentiation in a SRF/CArG box-dependent manner. Olfm2 physically interacted with SRF to counteract the association between SRF and HERP1 (also known as Hrt2, Hey2, Hesr2, and CHF1), a transcriptional repressor of SM genes, which further enabled Olfm2 to enhance SRF binding to CArG box in SM marker promoter, leading to transcriptional activation of SM marker genes. Together our results identify Olfm2 as a novel regulator for SM differentiation.
RESULTS

Olfm2 was induced during TGF-β-induced SM differentiation
TGF-β is an important determinant for SM lineage. To determine the role of Olfm2 in TGF-β-induced SM differentiation, we examined the expression of Olfm2 and SM markers in TGF-β-treated hES-MCs. As shown in Figure 1 , Olfm2 expression markedly increased soon after TGF-β induction, and TGF-β induced Olfm2 expression in a time-dependent manner, with an 8.4-fold increase after 48-h treatment (Figure 1, A and B) . Of importance, Olfm2 induction occurred earlier than expression of SM markers α-SMA, SM22α, and SMMHC (Figure 1 , A-E, and Supplemental Figure S1 ). Moreover, Olfm2 expression was observed in smooth muscle of human aorta tissue ( Figure 1F ). These data suggest that Olfm2 is involved in TGF-β-induced SM differentiation.
Olfm2 was required for TGF-β-induced SM differentiation
To determine whether Olfm2 plays a role in SM differentiation, we tested whether Olfm2 is required for TGF-β-induced SM marker expression. As shown in Figure 2 , A-E, knockdown of Olfm2 by an adenoviral vector expressing Olfm2 short hairpin RNA (shRNA; adenovirus [Ad]-shOlfm2) significantly attenuated TGF-β-induced SM marker expression, indicating that Olfm2 is essential for TGF-β-induced SM differentiation. To further determine the role of Olfm2 in SM differentiation, we tested whether Olfm2 alone can induce SM marker expression. As shown in Figure 2 , F-J, ectopic expression of Olfm2 in serum-starved hES-MCs induced 3.2-, 2.3-, and 3.6-fold increases in α-SMA, SM22α, and SMMHC expression, respectively. These results demonstrate that Olfm2 can promote SM marker gene expression.
TGF-β induced Olfm2 nuclear accumulation
To investigate how Olfm2 regulates TGF-β-induced SM differentiation, we first detected the subcellular location of Olfm2. Olfm2 immunostaining showed that Olfm2 was located in both cytoplasm and nuclei of TGF-β-untreated hES-MCs. TGF-β stimulation appeared to cause a majority of Olfm2 to accumulate in the nuclei ( Figure 3A ), suggesting that Olfm2 may serve as a nuclear factor to regulate transcriptional activation of SM markers. To confirm the Olfm2 nuclear location, we fractionated hES-MC protein extracts 1998; Manabe and Owens, 2001; Chen and Lechleider, 2004; Compton et al., 2006; Xie et al., 2007; Han et al., 2010; Yamaguchi et al., 2011) . We previously developed a novel in vitro model for TGF-β-induced SM differentiation from human embryonic stem cell-derived mesenchymal cells (hES-MCs; Boyd et al., 2009; Guo et al., 2013) . The precise molecular mechanisms governing the SM differentiation process, however, remain largely unknown.
Olfactomedin 2 (Olfm2) belongs to the family of olfactomedin domain-containing proteins, which contains at least 13 members in mammals (Karavanich and Anholt, 1998) . Olfm2 expression is developmentally regulated, and Olfm2 knockdown reduces eye size, inhibits optic nerve extension, and disrupts anterior CNS and head development, including neural crest cell-derived cartilaginous structures of the pharyngeal arches in zebrafish (Nakaya and Tomarev, 2007; Lee et al., 2008) . Olfm2 is able to form heterodimers with other family members, such as Olfm1, Olfm3, and myocilin, in early eye development (Sultana et al., 2011) . Effects of Olfm2 on eye development are likely associated with Pax6 signaling in developing zebrafish eyes (Lee et al., 2008) . Pax6 is a master transcriptional factor for eye development and functions and has been shown to physically interact with TGF-β, contributing to maintaining the functional status of eyes (Lang, 2004; Shubham and Mishra, 2012) . These data suggest a possible involvement of Olfm2 in the TGF-β signaling cascade during early eye development. In human, a R144Q substitution in Olfm2 protein is believed to be the disease-causing mutation in Japanese patients with open-angle glaucoma (Funayama et al., 2006) . However, the role of Olfm2 in vascular development, especially in SM differentiation, has never been reported.
In an analysis of TGF-β-induced SM differentiation of hES-MCs, we found that Olfm2 was dramatically up-regulated by TGF-β. We thus hypothesize that Olfm2 may be one of the TGF-β downstream targets mediating SM differentiation. Indeed, we found that Olfm2 TGF-β F Olfm2 can induce SM marker expression in the absence of SRF. As shown in Figure 4 , A-E, knockdown of SRF by shRNA blocked Olfm2-induced SM marker expression, suggesting that SRF was essential for Olfm2-induced SM differentiation. Moreover, CArG box mutations significantly inhibited Olfm2 induction of α-SMA and SM22α promoter activity (Figure 4 , F and G), suggesting that CArG box is indispensable for Olfm2 function. These data demonstrate that Olfm2 mediates SM differentiation in a SRF/CArGdependent manner.
Olfm2 physically interacted with SRF
Because Olfm2 function in SM differentiation relies on SRF/CArG, we sought to determine whether Olfm2 interacts with SRF. A coimmunoprecipitation (CoIP) assay using endogenous proteins extracted from hESMCs treated with vehicle or TGF-β showed that Olfm2 was coimmunoprecipitated with SRF ( Figure 5A ) and SRF was coimmunoprecipitated with Olfm2 ( Figure 5C ), demonstrating that Olfm2 physically interacted with SRF in hES-MCs. Their interaction was significantly enhanced by TGF-β, which was likely attributable to the increased expression of Olfm2 by TGF-β ( Figure 5 , A-D).
Olfm2 did not affect SRF-myocardin interaction
Myocardin (Myocd) is a transcriptional coactivator of SRF, and Myocd-SRF interaction is crucial for the differentiation of SM lineage (Wang et al., 2001 (Wang et al., , 2002 . Therefore we tested whether Olfm2 affects SRF and Myocd expression as well as their interaction. We found that the ectopic expression of Olfm2 had no effect on mRNA expression of either SRF or Myocd ( Figure 6 , A-C). To determine whether Olfm2 affects the interaction between SRF and Myocd, we transfected hES-MCs with FLAG-tagged Myocd expression plasmid and performed CoIP assays with endogenous SRF. As shown in Figure 6 , D and E, Olfm2 did not alter the interaction between SRF and Myocd. These data suggest that mechanisms other than modulation of SRF/Myocd binding are involved in Olfm2-mediated SM differentiation.
Olfm2 blocked HERP1 expression and its binding to SRF
HERP1 is a transcriptional repressor abundantly expressed in the developing vascular system (Nakagawa et al., 2000; Iso et al., 2001a,b) . HERP1 has been shown to physically associate with SRF and inhibit SM differentiation by interfering with SRF binding to CArG box (Doi et al., 2005) . Because both HERP1 and Olfm2 interact with SRF with opposite effects on SM differentiation, we hypothesize that TGF-β induction of Olfm2 promotes SM differentiation through inhibition of HERP1 expression or HERP1 binding to SRF. Indeed, TGF-β induced time-dependent suppression of HERP1 but up-regulated Olfm2 expression (Figure 7, A and B) . Of importance, Olfm2 overexpression decreased HERP1 mRNA expression into nuclear and cytoplasmic portions for Olfm2 Western blotting analysis. As shown in Figure 3 , B and C, before TGF-β treatment, only 38% of Olfm2 was located in the nuclei. TGF-β induction, however, increased the nuclear Olfm2 to 81% of the total protein, consistent with the immunostaining results in Figure 3A . These results indicate that TGF-β induces Olfm2 translocation to nuclei of hES-MCs.
Olfm2-induced SM marker expression depended on SRF/CArG
Although Olfm2 is a nuclear factor likely involving the SM gene transcription, analysis of Olfm2 protein structure using DNA-Binder software revealed that Olfm2 lacks the DNA-binding domain, suggesting that Olfm2 may serve as a coactivator for a key transcription factor that regulates SM differentiation. SRF is a key nuclear transcription factor regulating the expression of most SM marker genes by binding to highly conserved CArG box present within nearly all SM-specific promoters (Miano, 2003; Mack, 2011) . Because Olfm2 is critical for SM marker expression, we sought to determine whether Figure 7C ), whereas knockdown of Olfm2 effectively attenuated TGF-β-induced blockade of HERP1 expression (Figure 7, D and E) . These data suggest that Olfm2 mediated suppression of HERP1 by TGF-β. To determine whether Olfm2 affects HERP1 interaction with SRF, we performed CoIP assay in cells where Olfm2 expression was blocked. We found that TGF-β treatment inhibited HERP1-SRF interaction. However, knockdown of Olfm2 restored the HERP1 binding to SRF that was suppressed by TGF-β, indicating that Olfm2 mediated the TGF-β-induced dissociation of HERP1 from SRF (Figure 7, F and G) . These data demonstrate that Olfm2 regulates TGF-β-induced SM differentiation by removing the inhibitory effect of HERP1, that is, releasing SRF from HERP1.
Olfm2 was required for SRF binding to SM marker promoter
Because SRF binding to CArG box is crucial for SM gene transcription and Olfm2 mediated SRF release from HERP1, we sought to determine whether Olfm2 plays a role in SRF binding to SM marker gene promoter. Previous studies showed that SRF binding to CArG box is functionally important for SM22α promoter activity both in vitro and in vivo (Miano, 2003; McDonald et al., 2006) . We thus performed chromatin immunoprecipitation (ChIP) assays to determine whether Olfm2 affects SRF binding to this CArG box. As shown in Figure 8A , SRF weakly bound to the CArG box of SM22α promoter in a basal state. TGF-β treatment significantly enhanced the binding (Figure 8 , A and B), consistent with previous studies (Hautmann et al., 1999) . Knockdown of Olfm2, however, significantly diminished TGF-β-enhanced SRF binding to the promoter (Figure 8, A and B) , suggesting that Olfm2 is essential for SRF binding to SM marker promoter. Moreover, ectopic expression of Olfm2 in TGF-β-untreated cells dose dependently enhanced SRF binding to SM22α promoter (Figure 8, D and E) . To determine whether this is a common mechanism for Olfm2 to regulate SRF targets in SM differentiation, we tested the Olfm2 effect on SRF binding to another SM promoter, SMMHC promoter, and observed similar results as with SM22α promoter (Figure 8, A-F ). These data demonstrate that Olfm2 is a novel factor facilitating SRF binding to SM gene promoter, a key event for SM differentiation.
DISCUSSION
SM differentiation is an important process during vasculogenesis and angiogenesis, by which multipotential progenitor cells in the developing organism acquire contractile SM characteristics (Owens, 1995; Owens et al., 2004) . However, the precise molecular mechanisms controlling SM differentiation are not fully understood. It is well established that the vascular and nervous systems of vertebrates share many features, such as common signaling pathways and similar anatomy (Carmeliet, 2003; Melani and Weinstein, 2010; Tam and Watts, 2010) , suggesting that common factors might regulate both vascular and nervous development. Olfm2 is a developmentally regulated gene implicated in the early development of the CNS (Nakaya and Tomarev, 2007; Lee et al., 2008) . Our results suggest that Olfm2 also plays an important role in SM differentiation. Olfm2 is able to regulate TGF-β-induced SM differentiation of hES-MCs because knockdown of Olfm2 inhibits SM marker expression induced by TGF-β, whereas ectopic expression of Olfm2 induces SM markers expression, although to a much lesser extent than with TGF-β induction (Figure 2 vs. Figure 1) , consistent with other factors, such as SRF and Myocd, also being required for TGF-β-induced SM differentiation.
Of interest, TGF-β induces Olfm2 nuclear accumulation, making Olfm2 a nuclear factor involved in the transcriptional regulation of SM contractile genes. Analysis of Olfm2 protein sequence using cNLS Mapper Software reveals a nuclear localization signal, an 
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HERP1 also inhibits TGF-β-induced SM differentiation (King et al., 2006; Tang et al., 2008) . Olfm2 blocks HERP1 interaction with SRF and thus makes SRF abundant for SM marker promoter. Olfm2 also inhibits HERP1 expression. Second, Olfm2 facilitates SRF binding to SM promoters, given that blockade of Olfm2 expression diminishes TGF-β-induced SRF binding to both SM22α and SMMHC promoters. Finally, Olfm2 may enhance the affinity of SRF binding to SM promoters, given that the enrichment of SRFbinding region in SM22α and SMMHC promoters is significantly increased in Olfm2-overexpressed cells. Smad proteins are known to translocate to nuclei to regulate SM marker gene expression upon TGF-β induction. Smads appear to affect Olfm2 function by regulating its expression, given that knockdown of Smad3 completely and knockdown of Smad2 significantly block Olfm2 expression (Supplemental Figure S2 ). In addition, Smad3 inhibits Herp1 expression (Supplemental Figure  S3) , which is likely due to the induction of Olfm2. Of interest, both Smad3 and Olfm2 interact with SRF, but there is no detectable interaction between Olfm2 and Smad2 or Smad3 (unpublished data). One explanation is that Smad3 interacts with SRF in the early phase of SM lineage determination because Smad3 is phosphorylated and translocated into nuclei in a few minutes after TGF-β induction. Its phosphorylation/nuclear location declines after 1-2 h. Olfm2 interaction with SRF, however, occurs later, given that Olfm2 is not induced until after 1 h of TGF-β treatment. Therefore Olfm2 may interact with SRF at a slightly late phase to further promote SM marker gene transcription. Identification of Olfm2 function in SM gene transcription provides novel insights into TGF-β-induced SM differentiation. In the undifferentiated hES-MC cells or the initial phase of SM differentiation, Olfm2 is expressed at a low level, and SRF interacts with Smad3 and binds weakly to CArG box due to a substantial binding of HERP1 to SRF, resulting in a repressed state or very low level of SM marker gene transcription. When Olfm2 is induced by TGF-β via Smads and translocated into nuclei, it binds to SRF, causing SRF dissociation from HERP1, and thus removes the inhibitory effect of HERP1. Furthermore, Olfm2 facilitates and enhances SRF binding to CArG box in SM marker promoters, leading to a strong induction of SM marker expression (Figure 9 ). The homeostatic balance between Olfm2 and HERP1 expression appears to be an important factor in determining whether SM-specific marker genes can be effectively induced by TGF-β after the initial phase of SM differentiation.
MATERIALS AND METHODS
Cell culture and transfection
hES-MCs were maintained in αMEM (Fisher Scientific, Pittsburgh, PA) containing 10% mesenchymal stem cell-qualified fetal bovine serum (Hyclone) and 2 mM l-glutamine (Hyclone, Logan, UT). Cells were grown in serum-free medium for 16-24 h, followed by 11-amino acid sequence of GYPKRSAGEAF, at the region of AA364-374. This sequence can be recognized and bound by importin-α. Therefore Olfm2 is most likely translocated into the nuclei of hESMCs by TGF-β via an importin-α-mediated nuclear transport mechanism. Another possibility is that Olfm2 may form a complex with other signaling mediators, such as β-catenin or Notch intracellular domain. This complex may translocate into nucleus in a Smad3-dependent manner, which may be explored in the future.
Olfm2 function in SM marker expression/transcription is associated with SRF and CArG box because knockdown of SRF or CArG box mutation markedly inhibits Olfm2-induced SM marker gene expression and transcription. In fact, Olfm2 physically interacts with SRF, and this interaction is promoted by TGF-β. Of interest, Olfm2-SRF interaction does not affect Myocd-SRF interaction, suggesting that Myocd and Olfm2 may bind to different domains of the SRF protein.
However, Olfm2 appears to be critical for SRF binding to CArG box in SM marker promoters, which is attributed to the different roles of Olfm2. First, Olfm2 affects SRF binding to SM marker promoter by releasing SRF from its binding to HERP1. HERP1 is a downstream target of Notch signaling (Nakagawa et al., 2000; Iso et al., 2001a,b) . As a translational repressor, HERP1 inhibits Notchmediated SM differentiation via a negative feedback mechanism. with an 80-90% confluence using Lipofectamine LTX (Invitrogen, Grand Island, NY) according to the manufacturer's instruction.
Preparation of shRNA adenoviral vector
shRNA target sequence for Olfm2 was GCA CGT CCA GTT ACG AGT ACA CGG ACG TG. Double-stranded DNA-coding Olfm2 shRNAs were cloned into pRNAT-H1.1/ Adeno shuttle vector (Genscript, Piscataway, NJ). Adenovirus was packaged in 293 cells (Agilent Technologies, Santa Clara, CA) and purified by CsCl 2 gradient ultracentrifugation as previously described (Wang et al., 2011) . For adenoviral transduction, hES-MCs were transduced with 100-multiplicity of infection of control or shRNA adenovirus for 48-72 h.
Immunocytofluorescence staining hES-MCs were cultured on sterile coverslips and treated with TGF-β. Cells were then fixed with 1% paraformaldehyde (PFA) for 5 min, followed by methanol for 10 min at −20°C for Olfm2 staining. Anti-Olfm2 antibody was used at 1:100 in blocking buffer consisting of 5% bovine serum albumin in phosphate-buffered saline (PBS). Cells were then incubated with fluorescein isothiocyanate-conjugated secondary antibodies (1:100). Stained cells were imaged with a Nikon Eclipse 90i microscope, and images were captured with a Nikon 12.7MP digital Sight DS-Ri1 color camera.
Quantitative reverse transcription-PCR
Total RNA from cultured cells was extracted using TRIzol Reagent (Invitrogen) according to the manufacturer's instructions. Reverse transcription was performed using an iScript cDNA Synthesis kit (Bio-Rad). Quantitative reverse transcription-PCR (qPCR) was performed in a Mx3005P qPCR machine using SYBR Green master mix (Agilent Technologies). Each sample was amplified in triplicate. Primers for the qPCR were as follows. Olfm2, 5′-GGG AGG AGG TGA GGA ATC TC-3′ (forward) and 5′-CCA TCG TGT CAG TCA TCC AG-3′ (reverse); Myocd, 5′-TGC ATG CTG CTG TAA AGT CC-3′ (forward) and 5′-TAG CTG AAT CGG TGT TGC TG-3′ (reverse); SRF, 5′-CCT ACC AGC TTC ACC CTC AT-3′ (forward) and 5′-CGG GCT AGG GTA CAT CAT GT-3′ (reverse); and HERP1, 5′-TAG AGA AAA GGC GTC GGG AT-3′ (forward) and 5′-GTG TGC GTC AAA GTA GCC TT-3′ (reverse).
Western blotting
hES-MCs were cultured in αMEM or treated with TGF-β. Cells were washed two times with cold PBS, followed by protein extraction using radioimmunoprecipitation assay buffer (50 mmol/l Tris-HCI, pH 7.4, 1% Triton X-100, 0.25% [wt/vol] sodium deoxycholate, 150 mmol/l NaCl, 1 mmol/l ethylene glycol tetraacetic acid, 0.1% SDS, protease inhibitors, and phosphatase inhibitors). Protein concentration was measured using BCA Protein Assay reagent (Thermo Scientific, Waltham, MA ). A 5-or 10-μg amount of the lysates was resolved by SDS-PAGE and transferred to polyvinylidene fluoride membranes (Bio-Rad, Hercules, CA). Membranes were blocked incubation with TGF-β (1 ng/ml) for various times as needed. For transfections, cells were cultured in 12-or 6-well plates or 6-or 10-cm dishes and transfected with different plasmids 24 h after plating 
